Alnylam Pharmaceuticals Management
Management criteria checks 3/4
Alnylam Pharmaceuticals' CEO is Yvonne Greenstreet, appointed in Jan 2022, has a tenure of 2.25 years. total yearly compensation is $8.90M, comprised of 11% salary and 89% bonuses, including company stock and options. directly owns 0.038% of the company’s shares, worth $7.17M. The average tenure of the management team and the board of directors is 2.8 years and 8.4 years respectively.
Key information
Yvonne Greenstreet
Chief executive officer
US$8.9m
Total compensation
| CEO salary percentage | 11.0% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.04% |
| Management average tenure | 2.8yrs |
| Board average tenure | 8.4yrs |
Recent management updates
Recent updates
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking
Mar 19
Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Feb 18Alnylam's Huge Opportunity
Jan 12Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues
Dec 18Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares
Jun 23Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Oct 25Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo
Oct 07Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market
Sep 26Alnylam RNAi therapy for rare protein disorder gets EU approval
Sep 20Alnylam to offer $900M convertible senior notes
Sep 12Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy
Aug 29Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity
Aug 18APOLLO Hits A Bullseye, And Alnylam Logs Another Major Clinical Win
Aug 04Alnylam to target abdominal obesity after research data on gene mutation
Jul 27Alnylam Pharmaceuticals Heading Toward A Key Trial Read-Out
Jul 19Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?
Jun 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$9m | US$976k | -US$440m |
| Sep 30 2023 | n/a | n/a | -US$510m |
| Jun 30 2023 | n/a | n/a | -US$1b |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$5m | US$850k | -US$1b |
| Sep 30 2022 | n/a | n/a | -US$1b |
| Jun 30 2022 | n/a | n/a | -US$981m |
| Mar 31 2022 | n/a | n/a | -US$893m |
| Dec 31 2021 | US$9m | US$619k | -US$853m |
| Sep 30 2021 | n/a | n/a | -US$838m |
| Jun 30 2021 | n/a | n/a | -US$887m |
| Mar 31 2021 | n/a | n/a | -US$876m |
| Dec 31 2020 | US$3m | US$622k | -US$858m |
| Sep 30 2020 | n/a | n/a | -US$891m |
| Jun 30 2020 | n/a | n/a | -US$846m |
| Mar 31 2020 | n/a | n/a | -US$886m |
| Dec 31 2019 | US$3m | US$571k | -US$886m |
| Sep 30 2019 | n/a | n/a | -US$821m |
| Jun 30 2019 | n/a | n/a | -US$858m |
| Mar 31 2019 | n/a | n/a | -US$802m |
| Dec 31 2018 | US$3m | US$540k | -US$761m |
| Sep 30 2018 | n/a | n/a | -US$692m |
| Jun 30 2018 | n/a | n/a | -US$570m |
| Mar 31 2018 | n/a | n/a | -US$525m |
| Dec 31 2017 | US$985k | US$504k | -US$491m |
Compensation vs Market: Yvonne's total compensation ($USD8.90M) is below average for companies of similar size in the US market ($USD13.05M).
Compensation vs Earnings: Yvonne's compensation has increased whilst the company is unprofitable.
CEO
Yvonne Greenstreet (60 yo)
2.3yrs
Tenure
US$8,895,670
Compensation
Dr. Yvonne L. Greenstreet, MBChB, MBA, is Chief Executive Officer at Alnylam Pharmaceuticals, Inc. since January 01, 2022. Dr. Greenstreet joined the Alnylam Pharmaceuticals, Inc. on September 19, 2016. Sh...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$8.90m | 0.038% $ 7.2m | |
| CFO & Executive VP | 4.7yrs | US$3.22m | 0.015% $ 2.9m | |
| Chief Innovation Officer & Member of the Scientific Advisory Board | less than a year | US$3.32m | 0.018% $ 3.4m | |
| Chief Medical Officer and Executive VP of Development & Medical Affairs | 9.5yrs | US$3.23m | 0.0074% $ 1.4m | |
| Executive VP & Chief Commercial Officer | 3.3yrs | US$2.87m | 0.0041% $ 773.2k | |
| Chief Technical Operations & Quality Officer | 1.3yrs | no data | no data | |
| Senior VP | 4.9yrs | no data | 0.011% $ 2.0m | |
| Senior VP of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief Ethics & Compliance Officer | 1.6yrs | no data | no data | |
| Chief Corporate Development & Strategy Officer | 1.6yrs | no data | no data | |
| Chief Human Resource Officer | 4.9yrs | no data | no data | |
| Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board | no data | no data | no data |
2.8yrs
Average Tenure
55yo
Average Age
Experienced Management: ALNY's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.5yrs | US$8.90m | 0.038% $ 7.2m | |
| Chief Innovation Officer & Member of the Scientific Advisory Board | no data | US$3.32m | 0.018% $ 3.4m | |
| Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board | 8.5yrs | no data | no data | |
| Independent Director | 1.1yrs | US$658.72k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | US$516.04k | no data | |
| Independent Director | 8.3yrs | US$477.21k | 0.022% $ 4.1m | |
| Co-Founder | 21.8yrs | US$502.21k | 0.21% $ 39.4m | |
| Independent Chair of the Board & Lead Independent Director | 9.8yrs | US$531.36k | 0.00011% $ 20.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board & Independent Director | 12yrs | US$477.21k | 0.0029% $ 537.9k | |
| Independent Director | 5.8yrs | US$489.15k | 0% $ 0 |
8.4yrs
Average Tenure
68.5yo
Average Age
Experienced Board: ALNY's board of directors are considered experienced (8.4 years average tenure).